Expression of renal 11β-hydroxysteroid dehydrogenase type 2 is decreased in patients with impaired renal function

被引:40
|
作者
Quinkler, M
Zehnder, D
Lepenies, J
Petrelli, MD
Moore, JS
Hughes, SV
Cockwell, P
Hewison, M
Stewart, PM [1 ]
机构
[1] Univ Birmingham, Sch Med, Div Med Sci, Queen Elizabeth Hosp, Birmingham B15 2TT, W Midlands, England
[2] Univ Birmingham, Sch Med, Dept Nephrol, Queen Elizabeth Hosp, Birmingham B15 2TT, W Midlands, England
[3] Charite Univ Med Belin, Div Clin Endocrinol, Berlin, Germany
关键词
D O I
10.1530/eje.1.01954
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Renal 11 beta-hydroxysteroid dehydrogenase type 2 (11 beta-HSD2) enables selective access of aldosterone to the mineralocorticoid receptor (MR). Impaired 11 beta-HSD2 activity has been suggested in patients with hypertension as well as in patients with renal disease, where it may contribute to sodium retention, oedema and hypertension. To date, these studies have relied upon urinary cortisol (F) metabolite levels as surrogate markers of renal 11 beta-HSU2 activity. Methods: We have directly analysed renal 11 beta-HSD2 mRNA expression in 95 patients undergoing kidney biopsy using TaqMan real-time PCR. Serum and 24-h urine samples were used to document underlying renal function and endocrine parameters. Urinary F and cortisone (E) metabolites were analysed using gas chromatography/mass spectrometry. Results: Expression of 11 beta-HSD2 did not correlate with blood pressure or urinary Na/K ratio, but a significant positive correlation with creatinine clearance was observed (r = 0.284; P < 0.01). Immunofluorescence and confocal laser microscopy confirmed decreased 11 beta-HSD2 expression in patients with impaired renal function. For the first time, we showed that 11 beta-HSD2 mRNA expression correlated negatively with the urinary free (UF) F/E (UFF/UFE) ratio (r = 0.276; P < 0.05) as well as with the urinary tetrahydrocortisol + 5 alpha-tetrahydrocortisol/tetrahydrocortisone ((THF + alpha THF)/THE) ratio (r = 0.256; P < 0.05). No difference in 11 beta-HSD2 mRNA expression or in the UFF/UFE ratio was found between groups with no proteinuria, microalbummuria, moderate or severe proteinuria. In contrast, the urinary (THF + alpha THF)/THE ratio increased significantly (P < 0.05) in patients with severe albuminuria, suggesting increased hepatic 11 beta-HSD1 in those patients. Conclusions: These data suggest that renal 11 beta-HSD2 expression may be represented only marginally better, if at all, by the UFF/UFE than by the (THF + alpha THF)/THE ratio. Reduced renal 11 beta-HSD2 expression may lead to occupancy of the MR by glucocorticoids such as cortisol and may contribute to the increased sodium retention seen in patients with impaired renal function.
引用
收藏
页码:291 / 299
页数:9
相关论文
共 50 条
  • [1] IMPAIRED 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 2 ACTIVITY CONTRIBUTES TO RENAL SODIUM AVIDITY IN HUMAN CIRRHOSIS
    Fialla, A. Dam
    Thiesson, H. C.
    Bie, P.
    Hovind, P. H.
    de Muckadell, O. B. Schaffalitzky
    Krag, A.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S335 - S336
  • [2] Regulation of 11β-hydroxysteroid dehydrogenase type II expression in the renal epithelial cells
    Lecybyl, R
    Rubis, B
    Krozowski, Z
    Trzeciak, WH
    ENDOCRINE RESEARCH, 2003, 29 (02) : 211 - 216
  • [3] In vivo measurement of renal 11β-hydroxysteroid dehydrogenase type 2 activity
    Quinkler, M
    Oelkers, W
    Diederich, S
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (12): : 4921 - 4922
  • [4] Modulation of renal calcium handling by 11β-hydroxysteroid dehydrogenase type 2
    Ferrari, P
    Bianchetti, MG
    Sansonnens, A
    Frey, FJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 (10): : 2540 - 2546
  • [5] 11β hydroxysteroid dehydrogenase type 2 enzyme is expressed in normotensive and hypertensive patients with renal disease
    Stein-Oakley, AN
    Maguire, JA
    Dowling, J
    Perry, GJ
    Krozowski, Z
    Thomson, NM
    NEPHROLOGY, 1998, 4 (1-2) : 81 - 86
  • [6] Lower Renal Function Is Associated With Derangement of 11-beta Hydroxysteroid Dehydrogenase in Type 2 Diabetes
    Gant, Christina Maria
    Minovic, Isidor
    Binnenmars, Heleen
    de Vries, Laura
    Kema, Ido
    van Beek, Andre
    Navis, Gerjan
    Bakker, Stephan
    Laverman, Gozewijn Dirk
    JOURNAL OF THE ENDOCRINE SOCIETY, 2018, 2 (07): : 609 - 620
  • [7] Mineralocorticoid receptor and 11β-hydroxysteroid dehydrogenase type II expression in renal cell neoplasms
    Yakirevich, Evgeny
    Morris, David J.
    Tavares, Rosemarie
    Meitner, Patricia A.
    Lechpammer, Mirna
    Noble, Lelia
    de Rodriguez, Angela F.
    Gomez-Sanchez, Celso E.
    Wang, Li J.
    Sabo, Edmond
    DeLellis, Ronald A.
    Resnick, Murray B.
    AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2008, 32A (06) : 874 - 883
  • [8] Increased renal expression of aquaporin-3 in rats inhibited type 2 11β-hydroxysteroid dehydrogenase
    Ma, Seong Kwon
    Nam, Kwang Il
    Kim, Soo Wan
    Bae, Eun Hui
    Choi, Ki Chul
    Lee, JongUn
    KIDNEY & BLOOD PRESSURE RESEARCH, 2007, 30 (01): : 8 - 14
  • [9] Modulation of renal calcium handling by 11β-hydroxysteroid dehydrogenase type 2.
    Ferrari, P
    Bianchetti, MG
    Sansonnens, A
    Frey, FJ
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2002, 13 : 283A - 283A
  • [10] Impaired 11β-Hydroxysteroid Dehydrogenase Type 2 in Glucocorticoid-Resistant Patients
    Vitellius, Geraldine
    Delemer, Brigitte
    Caron, Philippe
    Chabre, Olivier
    Bouligand, Jerome
    Pussard, Eric
    Trabado, Severine
    Lombes, Marc
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2019, 104 (11): : 5202 - 5213